CA-BELKIN
Belkin, a leading consumer electronics brand for 40 years, today announced the availability of the BoostCharge Pro Magnetic Power Bank, built with Qi2 wireless charging technology. It is available to order today in 5K and 10K options, and in five fresh new colors – cyber lime, sand, pink, blue, and gold.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625730951/en/
Belkin BoostCharge Pro Magnetic Power Bank 5K in cyber lime, sand, pink, blue and gold color options. (Photo: Business Wire)
Unveiled earlier this year, Belkin’s Qi2 power bank lineup delivers up to 15W of fast charging power for iPhone 12 models and later, without the hassle of cables. They are engineered with an integrated kickstand for propping the phone up while streaming, reading or chatting, and work with magnetic and MagSafe cases up to 3mm thick. They are designed to fit perfectly on the back of iPhone without obstructing camera. “Power pass-through” allows for charging the power bank and attached devices in one simple action via USB-C port.
BoostCharge Pro Magnetic Power Bank 5K
- Fast charges iPhone 12 models and later up to 15W with Qi2 when battery pack is plugged in, and up to 7.5W when used as battery pack
- Provides up to 16 hours of additional battery life1
- Built with 1 x USB-C port to charge two devices simultaneously2
- Packaged with USB-C to USB-C cable to start charging right out of the box
- Available in black, cyber lime, sand, pink, and blue color options; gold available in European markets only
- $59.95 USD
BoostCharge Pro Magnetic Power Bank 10K
- Fast charges iPhone 12 models and later up to 15W with Qi2 (delivers 0-25% charge in 21 minutes3), or up to 20W with integrated USB-C cable
- Provides up to 35 hours of additional battery life4
- Built with 1 x USB-C port and integrated USB-C cable to charge three devices simultaneously5
- Available in black
- $99.95 USD
In line with Belkin’s commitment to build products more responsibly, the BoostCharge Pro Magnetic Power Bank offerings are made with a minimum of 72% post-consumer recycled materials (PCR) and packaged in 100% plastic-free packaging.
Media kit can be found HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
___________
1 Maximum additional video playback hours calculated by comparing the mAh capacity of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on differing factors for individual users.
2 When one device is charging: 7.5W wireless or USB-C 12W max output. When two devices are charging: 5W wireless + 5W max USB-C
3 Based on internal tests using iPhone 15; results may vary depending on various conditions.
4 Contains a 10,000 mAh internal battery. Amount of discharge to user’s device is less and may vary depending on various conditions. Maximum additional video playback hours calculated by comparing the capacity of the internal battery of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on conditions and use.
5 When one device is charging: 15W wireless, or USB-C 20W max output. When two devices charging: 7.5W wireless + 10W max USB-C. When three devices charging: 15W max shared
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625730951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom